By Bill Wichert ( February 17, 2022, 7:37 PM EST) -- Johnson & Johnson units have slammed Intas Pharmaceuticals Ltd. with a patent suit in New Jersey federal court seeking to block the India-based drugmaker from selling a generic version of the schizophrenia drug Invega Sustenna, saying the sales would infringe the asserted claims of a patent covering the drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.